Indaptus Therapeutics, Inc.
INDP
$6.52
-$0.55-7.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.77% | -11.83% | -7.33% | -2.49% | 2.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.83% | 0.81% | -6.18% | -5.60% | 5.71% |
| Operating Income | 0.83% | -0.81% | 6.18% | 5.60% | -5.71% |
| Income Before Tax | -7.71% | -5.15% | 2.60% | 1.21% | -7.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.71% | -5.15% | 2.60% | 1.21% | -7.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.71% | -5.15% | 2.60% | 1.21% | -7.71% |
| EBIT | 0.83% | -0.81% | 6.18% | 5.60% | -5.71% |
| EBITDA | 0.83% | -0.82% | 6.18% | 5.60% | -5.71% |
| EPS Basic | 27.74% | 16.19% | 11.67% | 4.51% | -6.27% |
| Normalized Basic EPS | 27.74% | 16.19% | 11.67% | 4.51% | -6.27% |
| EPS Diluted | 27.74% | 16.19% | 11.67% | 4.51% | -6.27% |
| Normalized Diluted EPS | 27.74% | 16.19% | 11.67% | 4.51% | -6.27% |
| Average Basic Shares Outstanding | 49.88% | 28.06% | 11.38% | 4.25% | 1.35% |
| Average Diluted Shares Outstanding | 49.88% | 28.06% | 11.38% | 4.25% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |